# Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

> **NCT04390958** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 70 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04390958
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-15
- **Primary completion:** 2022-06
- **Final completion:** 2022-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390958, "Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04390958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*